A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
provide for the prompt approval of drugs when safety 
information is added to labeling, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Prompt Approval of 
4
Safe Generic Drugs Act’’. 
5
SEC. 2. HEADING. 
6
Section 505 of the Federal Food, Drug, and Cosmetic 
7
Act (21 U.S.C. 355) is amended by adding at the end the 
8
following: 
9
22:06 Jun 07, 2021
H2831
2 
•HR 2831 IH
‘‘(z) PROMPT APPROVAL OF DRUGS WHEN SAFETY 
1
INFORMATION IS ADDED TO LABELING.— 
2
‘‘(1) GENERAL RULE.—A drug for which an ap-
3
plication has been submitted or approved under sub-
4
section (b)(2) or (j) shall not be considered ineligible 
5
for approval under this section or misbranded under 
6
section 502 on the basis that the labeling of the 
7
drug omits safety information, including contra-
8
indications, warnings, precautions, dosing, adminis-
9
tration, or other information pertaining to safety, 
10
when the omitted safety information is protected by 
11
exclusivity under clause (iii) or (iv) of subsection 
12
(c)(3)(E), clause (iii) or (iv) of subsection (j)(5)(F), 
13
or section 527(a), or by an extension of such exclu-
14
sivity under section 505A or 505E. 
15
‘‘(2) LABELING.—Notwithstanding clauses (iii) 
16
and (iv) of subsection (c)(3)(E), clauses (iii) and (iv) 
17
of subsection (j)(5)(F), or section 527, the Secretary 
18
shall require that the labeling of a drug approved 
19
pursuant to an application submitted under sub-
20
section (b)(2) or (j) that omits safety information 
21
described in paragraph (1) include a statement of 
22
any appropriate safety information that the Sec-
23
retary considers necessary to assure safe use. 
24
22:06 Jun 07, 2021
H2831
3 
•HR 2831 IH
‘‘(3) AVAILABILITY
AND
SCOPE
OF
EXCLU-
1
SIVITY.—This subsection does not affect— 
2
‘‘(A) the availability or scope of exclusivity 
3
or an extension of exclusivity described in sub-
4
paragraph (A) or (B) of section 505A(o)(3); 
5
‘‘(B) the question of the eligibility for ap-
6
proval under this section of any application de-
7
scribed in subsection (b)(2) or (j) that omits 
8
any other aspect of labeling protected by exclu-
9
sivity under— 
10
‘‘(i) clause (iii) or (iv) of subsection 
11
(c)(3)(E); 
12
‘‘(ii) clause (iii) or (iv) of subsection 
13
(j)(5)(F); or 
14
‘‘(iii) section 527(a); or 
15
‘‘(C) except as expressly provided in para-
16
graphs (1) and (2), the operation of this section 
17
or section 527.’’. 
18
Æ 
22:06 Jun 07, 2021
H2831
